Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel

• Main Authors: Jian-Ri Li (Author), Kun-Yuan Chiu (Author), Shian-Shiang Wang (Author), Cheng-Kuang Yang (Author), Chuan-Shu Chen (Author), Hao-Chung Ho (Author), Chi-Feng Hung (Author), Chen-Li Cheng (Author), Chi-Rei Yang (Author), Cheng-Che Chen (Author), Shu-Chi Wang (Author), Chia-Yen Lin (Author), Chao-Hsiang Chang (Author), Chiann-Yi Hsu (Author), Yen-Chuan Ou (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic c...